Dr. Piotr Witkowski, MD PhD
Claim this profileUniversity of Chicago Medical Center
Studies Type 1 Diabetes
Studies Diabetes Mellitus
6 reported clinical trials
6 drugs studied
Affiliated Hospitals
Clinical Trials Piotr Witkowski, MD PhD is currently running
Sernova Cell Pouch
for Type 1 Diabetes
This trial tests the safety and effectiveness of the Cell Pouch, an implantable device for people with Type 1 Diabetes who struggle with severe low blood sugar. The device holds insulin-producing cells in a natural, blood-rich environment to help them survive and function well. The study will monitor patients over several years to ensure the treatment is safe and works as intended.
Recruiting1 award Phase 1 & 28 criteria
AT-1501 + Islet Cell Transplant
for Type 1 Diabetes
AT-1501 is a monoclonal antibody. Antibodies are Y-shaped proteins that are produced naturally by the subject's immune system to attack and fight foreign substances that cause illness. Monoclonal antibodies are man-made proteins manufactured to serve as substitute antibodies to fight diseases. Monoclonal antibodies can restore, enhance, or mimic (copy) the immune system's attack process; they can also tone down the immune system. AT-1501 is thought to work by dampening down the immune system so that it will be less likely to attack the transplanted cells. For other types of transplants, like kidney, a drug called a calcineurin inhibitor is usually used to prevent rejection. That class of drugs can be toxic to islet cells. AT-1501 is an experimental agent that is anticipated to prevent rejection without harming the islet cells.
Recruiting1 award Phase 1 & 2
More about Piotr Witkowski, MD PhD
Clinical Trial Related6 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Piotr Witkowski, MD PhD has experience with
- Allogenic Islet Cells (human, U. Chicago)
- Intraportal Infusion Of Islet Cells
- Sernova Cell Pouch™
- Belatacept
- Allogenic Islet Cell Transplantation
- AT-1501
Breakdown of trials Piotr Witkowski, MD PhD has run
Type 1 Diabetes
Diabetes Mellitus
Contrast-induced Nephropathy
Kidney Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Piotr Witkowski, MD PhD specialize in?
Piotr Witkowski, MD PhD focuses on Type 1 Diabetes and Diabetes Mellitus. In particular, much of their work with Type 1 Diabetes has involved treating patients, or patients who are undergoing treatment.
Is Piotr Witkowski, MD PhD currently recruiting for clinical trials?
Yes, Piotr Witkowski, MD PhD is currently recruiting for 5 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Piotr Witkowski, MD PhD has studied deeply?
Yes, Piotr Witkowski, MD PhD has studied treatments such as Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells, Sernova Cell Pouch™.
What is the best way to schedule an appointment with Piotr Witkowski, MD PhD?
Apply for one of the trials that Piotr Witkowski, MD PhD is conducting.
What is the office address of Piotr Witkowski, MD PhD?
The office of Piotr Witkowski, MD PhD is located at: University of Chicago Medical Center, Chicago, Illinois 60637 United States. This is the address for their practice at the University of Chicago Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.